Literature DB >> 24252039

Primary and secondary surveys on epidemiology of Sjögren's syndrome in Japan.

Hiroto Tsuboi1, Hiromitsu Asashima, Chinatsu Takai, Shinya Hagiwara, Chihiro Hagiya, Masahiro Yokosawa, Tomoya Hirota, Hisanori Umehara, Atsushi Kawakami, Hideki Nakamura, Hajime Sano, Kazuo Tsubota, Yoko Ogawa, Etsuko Takamura, Ichiro Saito, Hiroko Inoue, Seiji Nakamura, Masafumi Moriyama, Tsutomu Takeuchi, Yoshiya Tanaka, Shintaro Hirata, Tsuneyo Mimori, Hajime Yoshifuji, Akiko Ohta, Isao Matsumoto, Takayuki Sumida.   

Abstract

OBJECTIVE: To characterize the epidemiology of Sjögren's syndrome (SS), including prevalence, disease type, extra-glandular involvement, satisfaction of diagnostic criteria sets, and treatment used in Japan.
METHODS: The Research Team for Autoimmune Diseases, the Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare conducted primary and secondary surveys on epidemiology of SS in 2011. The primary survey covered 4,729 out of 14,095 Japan-wide Hospital Departments to investigate the prevalence of SS. The secondary survey encompassed 214 Hospital Departments that agreed to the survey, to characterize disease type, extra-glandular involvement, satisfaction of diagnostic criteria sets, and treatments.
RESULTS: The number of patients with SS in Japan estimated by the primary survey was 68,483. The secondary survey involving data collected from 2,195 SS patients from 98 Hospital Departments showed that the mean age of patients was 60.8 ± 15.2 years, male/female ratio was 1/17.4, primary/secondary SS was about 60%/40% and glandular/extra-glandular form in primary SS was about 70%/25%. The satisfaction rate was 53.8% for the 1999 revised Japanese Ministry of Health criteria for the diagnosis of SS, 47.7% for the 2002 American-European Consensus Group classification criteria for SS and 49.6% for 2012 American College of Rheumatology classification criteria for SS. Corticosteroids were used by 752 of 2,195 patients (34%), immunosuppressants by 358 patients (16%), biologics by 68 patients (3%) and secretagogues by 695 patients (32%).
CONCLUSION: The surveys provided valuable information on the epidemiology of SS including prevalence, disease type, extra-glandular involvement, satisfaction of diagnostic criteria sets and treatments used today in Japan.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24252039     DOI: 10.3109/14397595.2013.843765

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  18 in total

1.  cDNA microarray analysis identifies NR4A2 as a novel molecule involved in the pathogenesis of Sjögren's syndrome.

Authors:  H Takahashi; H Tsuboi; H Asashima; T Hirota; Y Kondo; M Moriyama; I Matsumoto; S Nakamura; T Sumida
Journal:  Clin Exp Immunol       Date:  2017-07-21       Impact factor: 4.330

2.  Long-term prognosis and clinical course of choking-induced cardiac arrest in patients without the return of spontaneous circulation at hospital arrival: a population-based community study from the Shizuoka Kokuho Database.

Authors:  Takahiro Miyoshi; Hideki Endo; Hiroyuki Yamamoto; Koki Shimada; Hiraku Kumamaru; Nao Ichihara; Yoshiki Miyachi; Hiroaki Miyata
Journal:  BMC Emerg Med       Date:  2022-07-06

3.  Dental treatments, tooth extractions, and osteonecrosis of the jaw in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study.

Authors:  Takefumi Furuya; Shigeru Maeda; Shigeki Momohara; Atsuo Taniguchi; Hisashi Yamanaka
Journal:  J Bone Miner Metab       Date:  2016-07-02       Impact factor: 2.626

4.  Rheumatoid factor isotype and Ro epitope distribution in primary Sjögren syndrome and rheumatoid arthritis with keratoconjunctivitis sicca.

Authors:  Bob Meek; Johannes C Kelder; Anke M E Claessen; Arend Jan van Houte; Evert-Jan Ter Borg
Journal:  Rheumatol Int       Date:  2018-06-23       Impact factor: 2.631

5.  Risk factors for primary Sjögren syndrome-associated interstitial lung disease.

Authors:  Yong Wang; Ziliang Hou; Meihua Qiu; Qiao Ye
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

6.  Role of salivary anti-SSA/B antibodies for diagnosing primary Sjögren's syndrome.

Authors:  Pan Wei; Chunlei Li; Lu Qiang; Jing He; Zhanguo Li; Hong Hua
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2015-03-01

7.  Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren's syndrome with other sets of criteria in Japanese patients.

Authors:  Hiroto Tsuboi; Shinya Hagiwara; Hiromitsu Asashima; Hiroyuki Takahashi; Tomoya Hirota; Hisashi Noma; Hisanori Umehara; Atsushi Kawakami; Hideki Nakamura; Hajime Sano; Kazuo Tsubota; Yoko Ogawa; Etsuko Takamura; Ichiro Saito; Hiroko Inoue; Seiji Nakamura; Masafumi Moriyama; Tsutomu Takeuchi; Yoshiya Tanaka; Shintaro Hirata; Tsuneyo Mimori; Isao Matsumoto; Takayuki Sumida
Journal:  Ann Rheum Dis       Date:  2017-03-22       Impact factor: 19.103

8.  The Importance of Sex Stratification in Autoimmune Disease Biomarker Research: A Systematic Review.

Authors:  Kristy Purnamawati; Jamie Ann-Hui Ong; Siddharth Deshpande; Warren Kok-Yong Tan; Nihar Masurkar; Jackson Kwee Low; Chester Lee Drum
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

9.  Congenital limb deficiency in Japan: a cross-sectional nationwide survey on its epidemiology.

Authors:  Hiroshi Mano; Sayaka Fujiwara; Kazuyuki Takamura; Hiroshi Kitoh; Shinichiro Takayama; Tsutomu Ogata; Shuji Hashimoto; Nobuhiko Haga
Journal:  BMC Musculoskelet Disord       Date:  2018-07-27       Impact factor: 2.362

10.  Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks.

Authors:  Hiroto Tsuboi; Isao Matsumoto; Shinya Hagiwara; Tomoya Hirota; Hiroyuki Takahashi; Hiroshi Ebe; Masahiro Yokosawa; Chihiro Hagiya; Hiromitsu Asashima; Chinatsu Takai; Haruka Miki; Naoto Umeda; Yuya Kondo; Hiroshi Ogishima; Takeshi Suzuki; Shintaro Hirata; Kazuyoshi Saito; Yoshiya Tanaka; Yoshiro Horai; Hideki Nakamura; Atsushi Kawakami; Takayuki Sumida
Journal:  Mod Rheumatol       Date:  2014-09-11       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.